ArticleJournal of clinical tuberculosis and other mycobacterial diseases2026
Prevalence and risk factors associated with rifampicin-induced cholestasis jaundice among tuberculosis patients in high-incidence setting: A retrospective cohort study.
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Comments on "Prevalence and risk factors associated with rifampicin-induced cholestasis jaundice among tuberculosis patients in high-incidence setting: a retrospective cohort study".Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Comment on "Prevalence and risk factors associated with rifampicin-induced cholestasis jaundice among tuberculosis patients in high-incidence setting: A retrospective cohort study".Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- The critical link between clinical risk stratification and pharmacovigilance in tuberculosis therapy: implications for rifampicin-induced cholestatic jaundice.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Landouzy sepsis in a young adult with multiorgan failure: successful ECMO-assisted management using an individualized antituberculous regimen.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) remains a global public health challenge, with Thailand identified as a high-burden country for TB and TB-HIV infections by WHO in 2021-2025. While the standard TB treatment regimen-including isoniazid, rifampicin, pyrazinamide, and ethambutol-is highly effective but drug-induced liver toxicity is a serious concern. Among these toxicities, cholestatic jaundice, primarily linked to rifampicin, is understudied in terms of its prevalence, risk factors, and clinical outcomes. Methods: A retrospective cohort study was conducted. The medical records of TB patients who received rifampicin between January 1, 2017, and November 30, 2022, were reviewed. Cases of cholestatic jaundice during treatment were identified. Demographic data, clinical characteristics, laboratory results, and treatment outcomes were collected and analyzed. Risk factors were assessed using univariate and multivariate logistic regressions. Results: The prevalence of rifampicin-induced cholestatic jaundice was 1.52%. Key risk factors were age ≥ 60 years (aOR: 3.82, 95% CI: 2.07-7.06, p < 0.001) and BMI < 18.5 kg/m Conclusions: Rifampicin-induced cholestatic jaundice was observed in 1.52% of TB patients. Older age (≥60 years) and low BMI (<18.5 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.